399 related articles for article (PubMed ID: 19846130)
1. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
Parsons JK; Sarma AV; McVary K; Wei JT
J Urol; 2009 Dec; 182(6 Suppl):S27-31. PubMed ID: 19846130
[TBL] [Abstract][Full Text] [Related]
2. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
Parsons JK; Sarma AV; McVary K; Wei JT
J Urol; 2013 Jan; 189(1 Suppl):S102-6. PubMed ID: 23234610
[TBL] [Abstract][Full Text] [Related]
3. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know?
Sarma AV; Parsons JK; McVary K; Wei JT
J Urol; 2009 Dec; 182(6 Suppl):S32-7. PubMed ID: 19846144
[TBL] [Abstract][Full Text] [Related]
4. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
Parsons JK
J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
6. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Weiss N; Goodman P; Antvelink CM; Penson DF; Thompson IM
J Urol; 2007 Apr; 177(4):1395-400; quiz 1591. PubMed ID: 17382740
[TBL] [Abstract][Full Text] [Related]
7. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men.
Laven BA; Orsini N; Andersson SO; Johansson JE; Gerber GS; Wolk A
J Urol; 2008 May; 179(5):1891-5; discussion 1895-6. PubMed ID: 18353377
[TBL] [Abstract][Full Text] [Related]
8. Lower urinary tract symptoms, obesity and the metabolic syndrome.
Moul S; McVary KT
Curr Opin Urol; 2010 Jan; 20(1):7-12. PubMed ID: 19904208
[TBL] [Abstract][Full Text] [Related]
9. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
10. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
11. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia.
Parsons JK; Im R
J Urol; 2009 Oct; 182(4):1463-8. PubMed ID: 19683313
[TBL] [Abstract][Full Text] [Related]
12. Effects of obesity and weight loss in patients with nononcological urological disease.
Natarajan V; Master V; Ogan K
J Urol; 2009 Jun; 181(6):2424-9. PubMed ID: 19371912
[TBL] [Abstract][Full Text] [Related]
13. Consultation patterns in a community survey of men with benign prostatic hyperplasia.
Simpson RJ; Lee RJ; Garraway WM; King D; McIntosh I
Br J Gen Pract; 1994 Nov; 44(388):499-502. PubMed ID: 7538316
[TBL] [Abstract][Full Text] [Related]
14. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.
Dahle SE; Chokkalingam AP; Gao YT; Deng J; Stanczyk FZ; Hsing AW
J Urol; 2002 Aug; 168(2):599-604. PubMed ID: 12131317
[TBL] [Abstract][Full Text] [Related]
15. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
17. Prevention of benign prostatic hyperplasia disease.
Marks LS; Roehrborn CG; Andriole GL
J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
19. Review of exercise and the risk of benign prostatic hyperplasia.
Sea J; Poon KS; McVary KT
Phys Sportsmed; 2009 Dec; 37(4):75-83. PubMed ID: 20048544
[TBL] [Abstract][Full Text] [Related]
20. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
